Mr. Andre Larente reports

DIAGNOS AND THE THIRD LARGEST OPTICAL RETAILER IN COSTA RICA PILOTING CARA AND ITS TELEMEDICINE TECHNOLOGY

Diagnos Inc. has signed a contract with Optica Central, the third-largest optical chain store in Costa Rica, for implementation of CARA across Costa Rica.

"Optica Central, in collaboration with Aselcom, Diagnos's distributor, are pleased to start screening the population across our optical stores by providing Diagnos's proven AI solution for early detection of eye illnesses, such as diabetic retinopathy, as well as preventing blindness caused by diabetes. There is no doubt that Diagnos's experience in Costa Rica, and in other Latin American countries, has been at the forefront in proving its service with their remarkable technology," said Jefrey Salas, chief executive officer of Optica Central.

"At Diagnos, we have made our mark in different parts of the world, in collaboration with our partners and different stakeholders, where our AI technology and experience for serving patients has set the standard. We know that diabetic retinopathy has become the main cause of blindness worldwide occurring in patients aged 20 to 64 years. Costa Rica is no different from other countries, with almost 15 per cent of its population over 20 having diabetes, with less than 11 per cent diagnosed. At least 35 per cent have been identified with diabetic retinopathy within the diabetic population and 10 per cent are in jeopardy of having severe retinopathy that will affect their vision. Our technology is helping now, through Optica Central, to fill this gap," said Andre Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a Canadian corporation dedicated to early detection of critical health problems based of its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (Computer assisted retina analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the Food and Drug Administration (United States), European Conformity (Europe), Federal Commission for the Protection against Sanitary Risk (Mexico), and Saudi Food and Drug Authority (Saudi Arabia).

We seek Safe Harbor.